Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Values of the Immune Activation Markers CD38 and HLA-DR and the Ratio CD4/CD8 According to the Delay of Combined AntiRetroviral Therapy (c-ART) Initiation in Primary HIV-infected Patients (PRIMIMMUNO)

NCT02827227 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT02827227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02827227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Values of the Immune Activation Markers CD38 and HLA-DR and the Ratio CD4/CD8 According to the Delay of Combined AntiRetroviral Therapy (c-ART) Initiation in Primary HIV-infected Patients (PRIMIMMUNO)
Lead sponsor
Hospices Civils de Lyon
Phase
Observational
Overall status
Completed
Start date
January 31, 2014
Completion date
February 29, 2016
Enrollment
99 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-infected patients